Selva Therapeutics的封面图片
Selva Therapeutics

Selva Therapeutics

制药业

San Diego,CA 262 位关注者

Selva is developing therapeutic drugs for coronaviruses (SARS-CoV-2), filoviruses (Ebola) and Chagas Disease.

关于我们

Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. The company’s lead drug candidate, SLV213, is an orally available small molecule novel antiviral therapy with activity against a broad range of viruses that threaten global health, including SARS-CoV-2, the virus causing COVID-19. In addition, SLV213 has activity against Ebola and Nipah viruses and has completed preclinical development as a potential therapy against Chagas disease. Selva is headquartered in San Diego.

网站
https://www.selvarx.com
所属行业
制药业
规模
2-10 人
总部
San Diego,CA
类型
私人持股

地点

Selva Therapeutics员工

相似主页

查看职位

融资

Selva Therapeutics 共 1 轮

上一轮

A 轮

US$3,000,000.00

Crunchbase 上查看更多信息